Great Partnership News with High Times Out

New Post Public Reply Private Reply Replies (0) Message Board
SmallCapTraders
239
Great Partnership News with High Times Out Yesterday!

Lucy Scientific Discovery Announces Partnership with High Times® to Develop and Distribute a New Line of Psychoactive Products

‘Mindful by Lucy’


March 23, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. (“Lucy” or “The Company”) (NASDAQ:LSDI), a leading NASDAQ-listed psychedelic drug manufacturer, announced today the launch of a new line of unscheduled psychoactive compounds that will be available for sale throughout the United States, and where permitted throughout the rest of the world.

The first line in the new family of brands contains Amanita Muscaria mushrooms, a psychoactive adaptogen. The product leverages the compounds of these mushrooms, and a proprietary blend of other natural functional ingredients, to create a transformative experience for consumers worldwide. This product line is named ‘Mindful by Lucy’.

Lucy Scientific will produce Mindful with High Times, through a strategic partnership with High Times Holding Corp., the parent company of High Times®, the most well-known brand in cannabis. This collaboration aims to distribute and market the products initially through High Times' websites and social channels which reach over 10 million people across their owned and operated properties and social media accounts.

With a product launch targeted for Q2 2023, this new line is well-positioned to capitalize on the growing market for psychoactive alternatives, which Forbes predicts will double to over $5 billion in gross sales by 2025.

Lucy and High Times entered into a strategic investment agreement in January whereby Lucy received $2.5 million in advertising credits that will help launch the new brand into market through High Times channels and experiential events.

Chris McElvany, Chief Executive Officer of Lucy Scientific Discovery Inc., stated, “As awareness and acceptance of alternative treatments for various conditions, such as PTSD, anxiety disorders, and depression, continue to grow, adaptogens are emerging as a leading therapeutic remedy. This partnership between Lucy and High Times will enable the two companies to expand the reach of Lucy’s products and promote the potential health benefits to a broader audience.”

We would like to see a clean break above the 20 DMA at $1.63/share.

Recent IPO report on the first psychedelics manufacturing company to be listed on NASDAQ!

Lucy Scientific Discovery Inc. (NASDAQ: LSDI)

Hot sector, building momentum, low float, great setup

Current price $1.39/share as of market close 03/22/23
Public Float 10.15M Shares (Source: Yahoo Finance)
Range Since Inception $1.12 - $4.00/share

About Lucy

Lucy Scientific Discovery Inc. is a Nasdaq-listed (NASDAQ: LSDI) licensed producer of compounds for medicinal products. As granted by Health Canada’s Office of Controlled Substances, Lucy maintains a Controlled Drugs and Substances Dealer’s License, under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada), or a Dealer’s License. A Dealer’s License authorizes LSDI to develop, sell, deliver, and manufacture (through extraction or synthesis) certain pharmaceutical-grade active pharmaceutical ingredients, or APIs, used in controlled substances and their raw material precursors.

Here is What Lucy Offers (Source: https://www.lucyscientific.com/)

API and Target Formulation Production

By leveraging various scalable production methods, Lucy is uniquely positioned to effectively support current and future market needs at competitive prices.

Lucy's use of efficient and strategic manufacturing practices ensure a consistent and stable supply of the highest quality products from lab- to consumer-scale.

Research, Development and Commercialization Support

We will work directly with researchers and finished product manufacturers in a controlled and collaborative environment to facilitate healthy market growth.

Our team aims to maximize your probability of success while minimizing the time and costs required to achieve your goals.

Lucy (LSDI) has announced multiple breaking developments since its IPO last month.

LSDI is “focused on becoming the premier contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry”.

The company’s mission is to make their “products and research services available for the development of medicines and experimental therapies to address certain psychiatric health disorders and other medical needs including various mental health and addiction disorders”.

As the company stated in a recent press release:

“The shift toward a public health response to the drug crisis will provide greater opportunities for people who use substances to connect with a growing range of harm reduction and treatment options.”

In addition, as the company explained:

“We look forward to a time when Lucy can safely supply harm reduction programs globally, aiming to reduce lethal and or negative consequences associated with adulterated drug supply, particularly considering that fentanyl overdose is the leading cause of deaths among 18 to 45-year-olds in the United States,” said Chris McElvany, the Company’s CEO.

LSDI is “a licensed manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies”.

Furthermore, “The Company has licenses to manufacture several controlled substances, including Psilocybin; MDMA; LSD; Psilocin; N,N-DMT; Mescaline; and 2C-B”.

The company’s team “is composed of leading experts from pharmaceutical development, biotechnology, agriculture, applied chemistry, and consumer product manufacturing industries.”

In addition, the company’s “executive team brings deep experience in the development and commercialization of products featuring controlled substances as well as the navigation of regulatory structures applicable to these products”.

LSDI’s target customers “include an increasing number of the leading universities, hospitals and other public, private, and government institutions throughout the world that have launched research programs to conduct clinical studies aimed at understanding the therapeutic potential of a range of psychedelic substances”.

Recently, the company achieved multiple milestones.

On February 13, the company announced:

“Lucy Scientific Discovery Announces Closing of its $7.5 Million Initial Public Offering”
In addition, the company announced:

“Lucy Scientific Discovery to Ring Nasdaq Closing Bell Today in Celebration of its IPO”

Here are the company’s comments from this press release:

“We are excited to celebrate this victory at Nasdaq's iconic bell ringing ceremony, as today marks an important milestone for the Company,” said Chris McElvany, the Company’s CEO. “We are pleased to celebrate many months of hard work and team effort that led to the successful completion of our IPO. Seeing Lucy, a pioneer in psychedelics manufacturing, take the next step in its development by becoming the first psychedelics manufacturing company to be listed on NASDAQ is a huge accomplishment. This milestone marks a significant step in the company's growth and plans for expansion. We look forward to the opportunities ahead of us to continue working on improving mental health and finding sustainable solutions for treatment.”

Afterwards, the company announced another big accomplishment:

“Lucy Scientific Discovery Announces First Commercial Sale of Psilocybin Following Initial Delivery of DMT and 5-MeO-DMT to Hadassah BrainLabs”

Here are the company’s comments from this press release:

“This first commercial sale of psilocybin marks a key operational milestone for the company as we shift from pre revenue to revenue producing, and are excited about further opportunities ahead,” said Lucy’s CEO Chris McElvany. “This transaction establishes Lucy’s ability to supply the global psychedelic community with compounds and services. Not only will it strengthen our relationship with the researchers at Hadassah-Hebrew University Medical Center, whose research helps lay the academic foundations indicating the potential of psychedelics, it will lead to the improvement of lives of millions of people around the world.”

Most recently, on Friday, the company announced another significant development:

“Lucy Scientific Teams Up with Pramantha Group to Secure Key Government Contracts and Grants to Enhance its Manufacturing Capabilities”

As the company further explains:

LSDI “partnered with Pramantha Group, a firm specializing in securing key government contracts and grants, to enhance its drug manufacturing capabilities and meet the growing demand for essential drugs and medical supplies”.

Furthermore:

“By leveraging Pramantha Group's expertise in identifying and capturing strategic funding and contract opportunities, Lucy Scientific is well-positioned to compete for and secure key government contracts and grants. With access to these funds, Lucy Scientific will be able to expand its drug manufacturing capabilities and contribute to the country's healthcare needs.”

Here are some of the company’s comments from this press release:

"Our partnership with Pramantha Group will help us navigate the complex landscape of government contracts and grants and identify the right opportunities to support our growth and contribute to the country's healthcare needs," said Lucy Scientific Discovery’s CEO Chris McElvany. "We are excited to work with Pramantha Group to enhance our drug manufacturing capabilities and play a key role in securing the domestic drug supply. Pramantha has a proven track record and a commitment to excellence that makes it an ideal partner for Lucy as we look to grow our operations."

LSDI has multiple potential catalysts favoring a future of increased growth.

The chart is flashing oversold with an RSI of 35.34

A recent report from Data Bridge Market Research said that the psychedelic drugs market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 16.3% in the forecast period of 2020 to 2027 and expected to reach USD $6,859.95 million by 2027 from USD 2,077.90 million in 2019. Growing acceptance of psychedelic drugs for treating depression and increasing prevalence of depression and mental disorders are the factors for the market growth. Another report from Research And Markets upped the projection saying that the Psychedelic Drugs Market size is projected to reach USD $10.75 Billion by 2027, from USD 4.75 Bn in 2020 growing at a CAGR of 12.36% during 2021-2027.

It is important to note that approximately 70% of the psychedelics market is attributable to psychedelics manufacturers.

Full Analysis and Disclosure: https://mailchi.mp/broadstreetalerts/lsdi-lic...s-94477?e=[UNIQID]
Scroll down for more posts ▼

Top 10 Most Recent News Articles

WeWalk Brings Diabetes Support Back to Dubai Science Park

Updated Category News Views 104

Before sunrise on 21 November, a 3.5 km route in Dubai Science Park will carry a purpose bigger than sneakers and weekend fitness. WeWalk is returning for its seventh edition, with TECOM Group PJSC and Dubai Charity Association again putting the event behind support for children living with diabetes. That deserves to be said plainly: this is a community health effort, not...

Continue Reading
Action1's 3,688% Growth Puts Patching on Investor Maps

Updated Category News Views 87

Patch Management Finally Gets Some Respect Nothing makes a security buyer flinch faster than a machine carrying a known vulnerability for weeks, and Action1 has plainly found that nerve. The Houston-based autonomous endpoint management company says it was the fastest-growing endpoint management vendor on Deloitte's 2026 Technology Fast 500 for the second consecutive year,...

Continue Reading
Banks Face a Choice: Retreat or Fund Climate Resilience

Updated Category News Views 122

A flooded field can turn a prudent loan book into a social retreat overnight. That is the uncomfortable nerve in the Global Alliance for Banking on Values paper unveiled at COP31 in Antalya on November 19, 2026. Banks have become very practiced at mapping physical climate exposure, raising prices, tightening standards and stepping away. Fine, risk discipline matters. But...

Continue Reading
Abbe Lane Estate Puts Jewelry Demand on Full Display

Updated Category News Views 117

Glamour Is Walking Back Into the Auction Room Abbe Lane’s jewelry is not being offered as a vague nostalgia exercise; it is arriving with dates, a setting, and a clear split between two December sales. John Moran Auctioneers will lead with The Estate of Abbe Lane on Wednesday, December 9, 2026, at 10:00 a.m. PST, then follow with its Jewelry & Watches auction on...

Continue Reading
Humana's Medicare Audit Shock Puts Disclosure in Focus

Updated Category News Views 9

Medicare Advantage just reminded Wall Street that reimbursement plumbing can wreck a perfectly calm-looking stock in a hurry. Humana shareholders watched that lesson land hard on November 18, when reports surfaced of a proposed federal CRUSH rule aimed at fraud, waste, and improper payments in the program. The reported response in NYSE:HUM was ugly: an early account put...

Continue Reading
LiberNovo's Black Friday Chair Sale Tests Premium Demand

Updated Category News Views 81

Ergonomic chairs are not impulse purchases, and LiberNovo knows it. Its Black Friday push in the United States and Canada runs through November 30, throwing discounts, gifts, prize-wheel entries and loyalty points at buyers considering a fairly expensive piece of office equipment. That is a lot of promotional machinery for a chair sale, but the underlying pitch is...

Continue Reading
A Quanzhou Table Offers China Beyond the Headlines

Updated Category News Views 84

Steam rising from a Quanzhou table can carry more weight than another polished speech about cultural exchange. That is the sensible instinct behind Home Banquets with Master Chefs, the CCTV-4 series using regional meals to explore geography, customs and memory. It is not trying to explain China through a pile of statistics or a museum-label summary. It starts where people...

Continue Reading
Corner Bakery Bets on Holiday Catering Convenience

Updated Category News Views 22

A $50 carrot on a $350 catering tab tells you exactly where Corner Bakery sees the holiday battlefield: not in one lonely cookie sale, but in the larger group order that can make a restaurant’s day. The chain is pushing holiday catering through November and December, pairing that discount with bakery trays, meals for groups and a promise to handle delivery setup. It is...

Continue Reading
Dutch Solar Homes Face a 2027 Net Metering Reset Ahead

Updated Category News Views 72

A policy switch buried in a Dutch calendar is about to rearrange millions of kitchen-table energy calculations. On 1 January 2027, the Netherlands ends net metering, or salderingsregeling, and households with solar panels will no longer offset exported power against electricity bought from the grid. That is not some abstract regulatory footnote. It changes the value of...

Continue Reading
Mudrick Urges Doncasters to Test a Strategic Sale Now

Updated Category News Views 36

Castings are rarely glamorous until nobody can get them, and Mudrick Capital is betting that ugly little industrial reality could make Doncasters worth far more in a takeover than the market currently credits. The event-driven investor, which says it owns roughly 4.3% of DPC Holdings Limited, has asked the board to quietly evaluate strategic alternatives, including a sale...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Online Auction of Distinctive Ranch Properties

Updated Category News Views 373

Exciting Online Auction of Distinctive Ranch Properties SVN Auction Services, LLC and SVN | Walt Arnold Commercial Brokerage are thrilled to announce an exciting online auction featuring a unique ranch retreat. Set on 52 acres, this estate boasts a spacious 4,400 square foot main home along with seven handcrafted log and stone cabins. This is a rare chance to acquire a...

Continue Reading
Teladoc Health Unveils Innovative Wellbound EAP Initiative

Updated Category News Views 461

Introduction to Teladoc Health's Wellbound EAP Discover how Teladoc Health, a leader in virtual healthcare, is revolutionizing employee wellness with the launch of Wellbound, a new Employee Assistance Program (EAP). This innovative initiative is designed to enhance employee engagement and support workforce health across various sectors. A Comprehensive Approach to...

Continue Reading
Mirion Technologies Achieves New Heights with Stock Surge

Updated Category News Views 121

Mirion Technologies Reaches a Milestone Stock High Mirion Technologies Inc. (NYSE: MIR) has made headlines recently, achieving a remarkable new 52-week high of $14.81. This significant achievement underscores the company's strong performance, with an impressive year-over-year stock value increase of over 113%. Investors are expressing heightened confidence in Mirion’s...

Continue Reading
Understanding Short Interest and Market Sentiment for BCH

Updated Category News Views 127

Short Interest Trends for Banco De Chile Banco De Chile's short percent of float has recently increased by 5.0% since the last report. Currently, there are approximately 519 thousand shares sold short, representing 0.21% of all available trading shares. Given the current trading volume, it would take traders about 2.09 days to cover their short positions on average....

Continue Reading
Pixalate Insights Reveal Top Brazilian Publishers for Ads

Updated Category News Views 170

Celebrating Quality in Programmatic Advertising As the digital landscape evolves, ensuring quality in programmatic advertising is more crucial than ever. In January 2025, Pixalate, a global leader in ad fraud prevention and compliance analytics, released its much-anticipated Publisher Trust Index (PTI) for Brazil. This index sheds light on the top publishers and apps...

Continue Reading